Calcium–phosphorus product concentration is a risk factor of coronary artery disease in metabolic syndrome.

Abstract: Background: High serum phosphorus and the calcium–phosphorus product concentration has been associated with increased mortality and cardiovascular events in patients with chronic kidney disease. Objective: This study was designed to determine the relationship between calcium–phosphorus product concentration and the presence of coronary artery calcification in subjects with metabolic syndrome (MetS). Methods: We reviewed the medical records of 2056 general subjects with a mean age of 55.1 ± 9.9 years and a glomerular filtration rate of 88.9 ± 16.2 mL/min/1.73 m2. The enrolled subjects consisted of 384 (18.7%) subjects with MetS and 1672 (81.3%) subjects without MetS. The severity of coronary artery calcification was assessed by the coronary artery calcification score (CACS) using multi-detector computed tomography (MDCT). Results: The CACS correlated with calcium–phosphorus product concentration in subjects with MetS (r = 0.184, P < 0.01). The odds ratio of calcium–phosphorus product concentration having CACS >50 was 1.053 in subjects with MetS (P < 0.05). After adjustment for age, sex, diabetes, and dyslipidemia, calcium–phosphorus product concentrations had a positive correlation with CACS in subjects with MetS. In single regression analysis, calcium–phosphorus product concentration as independent variable was the significant predictor of CACS in subjects with MetS. Using a multivariate analysis, calcium–phosphorus product concentration remained a significant factor associated with CACS in subjects with MetS. Conclusions: Calcium–phosphorus product concentration was weakly associated with CACS and an independent factor predicting for CACS by MDCT in subjects with MetS. These results suggest that calcium–phosphorus product concentration might be considered as a risk factor of coronary artery disease in subjects with MetS. [Copyright &y& Elsevier]